Former chief executive of GlaxoSmithKline (GSK), Sir Andrew Witty has been chosen to chair the Accelerate Access Collaborative (AAC) in efforts from the UK Government to accelerate the approval of important new medical therapies. The organisation will be responsible for coordinating the various government bodies that will decide which new treatments should be selected for the Government’s new Accelerated Access Pathway (AAP) which will come...
Life sciences incubation business, BioCity, are set to further expand in Aberdeen’s world-class life sciences cluster following success at the headquarters in Nottingham. Delivered by BioCity Group in partnership with private sector economic development body Opportunity North East (ONE), the ONE Life Sciences Accelerator Programme will launch with a boot camp in early December, followed by a 12-week DEVELOP programme starting in January 2018. Toby...
We are delighted to open the call for nominations for this year’s Life Sciences Awards. There are seven awards this year including three new categories designed to shine a light on the sector’s global successes and rising stars: Business Leadership Award (2017) Rising Stars: Extraordinary Talent (2017) Rising Stars: High-Growth Company (2017) Innovation Award Innovative Collaboration Award Global Impact Award Investment of the Year Award...
The Medical Visualisation Product Forge took place over the weekend. Product Forge partnered with Toshiba Medical Visualisation Systems Europe and Scottish Health Innovations to host a hackathon that aimed to create innovations that would help to improve clinical pathways and advance precision medicine. The event saw 8 teams work over the weekend to develop their concepts in to digital prototypes with guidance and mentorship from...
Capsugel announced that they have expanded clinical trial capabilities as well as increased development and manufacturing capabilities for specialised drug products using liquid-filled hard capsule (LFHC) technology. The expansion at Capsugel’s Edinburgh facility will also include a new isolators for high containment pre-dispensing and compounding, high- and low-shear compounding and holding tanks, an additional high-speed encapsulation machine, a capsule banding unit, and added high-containment capabilities for...
Concept Life Sciences (Concept), announced they have acquired Aquila BioMedical (Aquila), an innovative pre-clinical contract research organisation with expertise in immuno-oncology, immunology and multiplex histology. Aquila develop therapeutics for oncology, biomarker discovery and target expression, with services covering a wide range of in vitro and in vivo proof-of-concept studies. The acquisition will be a significant addition to the range of integrated services Concept provide as...